<DOC>
	<DOC>NCT01477242</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-emetic effect of oral ondansetron. For this evaluation, the investigators will perform a multi-center, double-blind, placebo-controled, randomized study. The investigators assumption is that oral ondansetron prior to intramuscular ketamine will reduce the occurrence of ketamine-induced vomiting.</brief_summary>
	<brief_title>The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department</brief_title>
	<detailed_description>Methods - a multi-center, double-blind, placebo-controled, randomized study ( 4 tertiary hospital ED) - survey for the occurrence of vomiting at ED and after discharge Primary outcome - the number of vomiting at ED and at home Secondary outcome - parent's satisfaction and ED length of stay</detailed_description>
	<mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>children under 18 years of age children who are planned to admit ketamine intramuscular injection children with ASA classification class I or II don't want to enroll to study children with condition of contraindication of ketamine (IICP, IIOP, psychosis, brain tumor, thyroid disease, porphyria) children with condition of contraindication of ondansetron (hypersensitivity to 5HT3 antagonist, Long QT syndrome, severe liver failure, obstructive ileus) children under 3 months of age children whose weight are over 30 kg children managed by other drug with ketamine</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>vomiting</keyword>
	<keyword>anti-emetics</keyword>
	<keyword>ketamine</keyword>
	<keyword>sedation</keyword>
</DOC>